These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31251426)

  • 1. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
    Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
    Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Retention in an Outpatient Behavioral Health Clinic With Buprenorphine.
    Montalvo C; Stankiewicz B; Brochier A; Henderson DC; Borba CPC
    Am J Addict; 2019 Sep; 28(5):339-346. PubMed ID: 31066985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Discontinuation of Buprenorphine Therapy for Opioid Use Disorder Among Privately Insured Adults.
    Agbese E; Leslie DL; Manhapra A; Rosenheck R
    Psychiatr Serv; 2020 Aug; 71(8):779-788. PubMed ID: 32264801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking patients with buprenorphine treatment in primary care: Predictors of engagement.
    Simon CB; Tsui JI; Merrill JO; Adwell A; Tamru E; Klein JW
    Drug Alcohol Depend; 2017 Dec; 181():58-62. PubMed ID: 29035705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of early dropout in outpatient buprenorphine/naloxone treatment.
    Marcovitz DE; McHugh RK; Volpe J; Votaw V; Connery HS
    Am J Addict; 2016 Sep; 25(6):472-7. PubMed ID: 27442456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 13. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
    Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
    Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge.
    Lee CS; Liebschutz JM; Anderson BJ; Stein MD
    Am J Addict; 2017 Oct; 26(7):667-672. PubMed ID: 28324627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.
    Kumar N; Stowe ZN; Han X; Mancino MJ
    Am J Addict; 2016 Oct; 25(7):542-8. PubMed ID: 27629823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine Provision by Early Career Family Physicians.
    Tong ST; Hochheimer CJ; Peterson LE; Krist AH
    Ann Fam Med; 2018 Sep; 16(5):443-446. PubMed ID: 30201642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.
    Stein MD; Conti MT; Herman DS; Anderson BJ; Bailey GL; Noppen DV; Abrantes AM
    Am J Addict; 2019 Jul; 28(4):270-276. PubMed ID: 30993833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.